

4th International Conference on Radiopharmaceutical Therapy (ICRT 2011)

In Conjunction with 10th AGM of Asian Regional Cooperative Council for Nuclear Medicine (ARCCNM)

28 Nov – 2 Dec 2011

New World Saigon Hotel, Ho Chi Minh City, Vietnam

DAY 1: MONDAY, 28 NOVEMBER 2011

0800 – 1600	REGISTRATION	Ben Thanh Hall Foyer, Level 1
0900 – 1700	NATIONAL COORDINATORS' MEETING OF AN IAEA REGIONAL TECHNICAL COOPERATION PROJECT	To Be Advised
1200 – 1300	LUNCH / TRADE EXHIBITION	
1300 – 1445	PRE-CONGRESS NUCLEAR CARDIOLOGY SYMPOSIUM: SESSION I	Ben Thanh Hall 1 & 2, Level 1
	Session Chairpersons: 1. Prof Vo Thanh Nhan, Vietnam 2. Prof Henry Bom, CNU Medical School, Korea	
1300 – 1330 (O-6)	Myocardial Perfusion Imaging as a Gatekeeper for Coronary Angiography Dr Carlos D Libhaber, Nuclear Cardiology, University of the Witwaterstrand, Johannesburg, South Africa	
1330 – 1400 (O-2)	Clinical Roles of Myocardial Viability Assessment Prof Zuo-Xiang He, Nuclear Medicine, Fu Wai Hospital & Cardiovascular Institute, Beijing, China	
1400 – 1430 (O-3)	Nuclear Medicine in Heart Failure Dr R Giubbini, Chair of Nuclear Medicine, University of Brescia, Italy (IAEA Expert)	
1430 – 1450	ORAL PRESENTATIONS	
1430 – 1440 (O-4)	A Custom-Built Software Tool for Data Storage and Analysis of Acquisition and Processing Parameters For Tc-99m and Tl-201 MPI with Different Imaging Systems Dr Charalambos Yiannakkaras, Medical Physics, Nicosia General Hospital, Nicosia, Cyprus	
1440 – 1450 (O-5)	Construction of a Dynamic Cardiac Phantom to Optimize the Diagnostic Value in SPECT Myocardial Perfusion Imaging Dr Yiannis Parpottas, General Department (Physics-Math), Frederick University, Nicosia, Cyprus	
1450 – 1500	COFFEE / TEA / TRADE EXHIBITION	Ben Thanh Hall Foyer Pre-Function Area, Level 1
1500 – 1700	PRE-CONGRESS NUCLEAR CARDIOLOGY SYMPOSIUM: SESSION II	Ben Thanh Hall 1 & 2, Level 1
	Session Chairpersons: 1. Dr Bùi Diệu Hằng, Vietnam 2. Dr Vikram Lele, Nuclear Medicine & PET-CT, Jaslok Hospital & Research Centre, Mumbai, India	
1500 – 1530 (O-1)	Direct Myocardial Ischemia Imaging Prof Zuo-Xiang He, Nuclear Medicine, Fu Wai Hospital & Cardiovascular Institute, Beijing, China	
1530 – 1600 (O-7)	Multimodality Assessment of Myocardial Ischemia and Viability – Part 1 (CT/MRI/Echo) Dr Felix Keng, Nuclear Cardiology, National Heart Centre, Singapore	
1600 – 1630 (O-8)	Multimodality Assessment of Myocardial Ischemia and Viability – Part 2 (SPECT & PET) Prof Henry Bom, CNU Medical School, Korea	
1630 – 1700	Discussions	
1730 – 1830	WARMTH GOVERNING BODY MEETING (GOVERNING BODY MEMBERS ONLY)	
1930 – 2200	WELCOME DINNER	Grand Mekong Ballroom, Level 1
2200	END OF DAY 1	

4th International Conference on Radiopharmaceutical Therapy (ICRT 2011)

In Conjunction with 10th AGM of Asian Regional Cooperative Council for Nuclear Medicine (ARCCNM)

28 Nov – 2 Dec 2011

New World Saigon Hotel, Ho Chi Minh City, Vietnam

DAY 2: TUESDAY, 29 NOVEMBER 2011

0730 – 1600 **REGISTRATION** Ben Thanh Hall Foyer, Level 1

0800 – 0815 **OPENING REMARKS**

0815 – 0955 **SCIENTIFIC SESSION I: THYROID I** Ben Thanh Hall, Level 1

Session Chairpersons:

1. Prof Adil Al-Nahhas, Nuclear Medicine, Imperial College, London, United Kingdom
2. Dr Tran Van Thiep, Vietnam

0815 – 0840 **Radioiodine Therapy of Thyroid Cancer at Seoul National University (SNU) Hospital**
(O-9) Prof June-Key Chung, Nuclear Medicine, Seoul National University Hospital, Seoul, Korea

0840 – 0905 **Thyroid Cancer and the Benefit of rhTSH in Treatment**
(O-10) Dr Knut Liepe, Nuklearmedizin, Klinikum Kassel, Germany

0905 – 0930 **Thyroid Cancer: Anything New?**
(O-11) Prof Irene Virgolini, Nuclear Medicine & PET, Medical University of Innsbruck, Innsbruck, Austria

0930 – 0955 **Eurasian Federation of Oncology: Ventures for Collaboration with WARMTH**
(O-12) Dr Somasundaram Subramanian, Director, Eurasian Federation of Oncology, Surgeon (Head & Neck, Melanoma), Department of Biotherapy, N. N. Blokhin Russian Cancer Research Center, Moscow, Russia

0955 – 1015 **ORAL PRESENTATIONS** Ben Thanh Hall, Level 1

0955 – 1005 **Effect of Short Term Metformin Therapy Associated with Levothyroxin Dose Decrement on TSH and Thyroid Hormone Levels in Patients with Thyroid Cancer**
(O-13) Dr Seyed Rasoul Zakavi, Nuclear Medicine Research Center, Emam Reza Hospital / Mashhad University of Medical Sciences, Mashhad, Iran

1005 – 1015 **Breast Cancer and Autoimmune Thyroiditis: Does the Sodium Iodide Symporter Play a Role?**
(O-14) Dr Jefferson Pagsisihan, Nuclear Medicine, St. Lukes Hospital, Quezon City, Philippines

1015 – 1100 **COFFEE / TEA / TRADE EXHIBITION** Ben Thanh Hall Foyer
Pre-Function Area, Level 1

1015 – 1100 **POSTER PRESENTATIONS: THYROID DISEASES** Ben Thanh Hall Foyer
Pre-Function Area, Level 1

Session Coordinators:

1. Dr Ngo Thuy Trang, MD, The Nuclear Medicine and Oncology Center, Hanoi, Vietnam
2. Dr Duong Duc Binh, Nuclear Medicine, Danang Hospital, Danang City, Vietnam

(P-1) **Is 99Tcm Thyroid Planar Imaging Suitable for Evaluating Residue Thyroid after Thyroidectomy: Comparing with I131 Scan after Radioiodine Therapy**
Dr Shuqi Wu, Nuclear Medicine, Xinhua Hospital, Shanghai Jiaotong University, Shanghai, China

(P-2) **Tc-99m MIBI Scintigraphy For Post-Therapy Differentiated Thyroid Carcinoma Patients Follow Up**
Dr Ryan Yudistiro, Nuclear Medicine, Dr Hasan Sadikin Hospital, Bandung, Indonesia

(P-3) **Effect of I-131 Large Dose Thyroid Carcinoma Therapy on Sub Mandibular & Parotid Gland. Quantitative Analysis of Salivary Excretion Pre and Post Therapy**
Dr Om Prakash Sinha, Nuclear Medicine, Gujrat Cancer & Research Institute, Ahmedabad, India

(P-4) **Serum Thyroglobulin Level Alone is not Enough to Monitor Persistence or Recurrence Disease of Differentiated Thyroid Carcinoma**
Dr Aisyah Elliyanti, Radiology / Nuclear Medicine, Dr M Djamil Hospital / Faculty of Medicine Andalas University, Padang, Indonesia

(P-5) **Pattern of Metastases in Well Differentiated Thyroid Microcarcinoma**
Dr Fithriany Syamsuddin, Nuclear Medicine, Dr Hasan Sadikin Hospital / Padjajaran University, Bandung, Indonesia

(P-6) **Outcome of Pregnancy after Radioactive Iodine Treatment**
Dr Dessie Yulistiawaty, Nuclear Medicine, Dr Hasan Sadikin Hospital, Bandung, Indonesia

(P-7) **Radioactive Iodine Ablation in Young Adults With Differentiated Thyroid Carcinoma**
Dr Yustia Tuti Jelani, Nuclear Medicine, Dr Hasan Sadikin Hospital, Bandung, Indonesia

4th International Conference on Radiopharmaceutical Therapy (ICRT 2011)

In Conjunction with 10th AGM of Asian Regional Cooperative Council for Nuclear Medicine (ARCCNM)

28 Nov – 2 Dec 2011

New World Saigon Hotel, Ho Chi Minh City, Vietnam

DAY 2: TUESDAY, 29 NOVEMBER 2011 (CONT'D)

(P-8)	Applications of Nuclear Medicine Techniques in Diagnosis and Treatment of Differentiated Thyroid Carcinoma: Results in Vietnam Dr Phan Sy An An, Nuclear Medicine & Oncology, Bach Mai, Hanoi, Vietnam
(P-9)	Differentiated Thyroid Cancer Ablation: 5 Years Experience in Limassol General Hospital Dr Ourania Demetriadou, Nuclear Medicine, Limassol General Hospital, Limassol, Cyprus
(P-10)	Efficiency Predictive Factors of Radio-Iodine Ablation in Differentiated Thyroid Cancer Dr Chatti Kaouthar, Nuclear Medicine, Sahloul University Hospital, Sousse, Tunisia
(P-11)	Lymph Node Metastasis of Differentiated Thyroid Cancer More Frequently Develops into Non-Iodine-Avid Than Lung or Bone Metastasis Dr Fang Feng, Nuclear Medicine, Xinhua Hospital, Shanghai, China
(P-12)	The Outcome of 23 Patients Differentiated Thyroid Carcinoma with Lung Metastase After Radiothyroablation with Iodine-131 Dr Gani Gunawan, Nuclear Medicine, Hasan Sadikin General Hospital, Bandung, Indonesia
(P-13)	Head Mass with Radioactivity Uptake in Patient with Thyroid Carcinoma Dr Nopriwan Agamawan Salam, Nuclear Medicine, Hasan Sadikin Hospital, Bandung, Indonesia
(P-14)	Recent Status of Radioiodine Therapy for Patients with Primary Hyperthyroidism and Differentiated Thyroid Carcinoma in Bangladesh Dr Shahana Afroz, Biological Science, Bangladesh Atomic Energy Commission, Dhaka, Bangladesh
(P-15)	Role of Ultrasonography (USG), Radionuclide Scan (RNS) and Fine Needle Aspiration Cytology (FNAC) in Thediagnosis of Malignancy in Solitary Thyroid Nodule Dr Akhter Nahid, Nuclear Medicine, Centre for Nuclear Medicine & Ultrasound, Dinajpur, Dhaka, Bangladesh
(P-16)	Unusual Metastasis in Papillary Thyroid Carcinoma: A Case Report Dr Hapsari Indrawati, Nuclear Medicine, Hasan Sadikin Hospital, Bandung, Indonesia
(P-17)	Effect of Low Dose Radioiodine Therapy in Respect to Amount of Post-Operative Thyroid Tissue (With Metastasis or Not) Dr AKM Fazlul Bari, Thyroid Medicine, Institute of Nuclear Medicine and Ultrasound, Dhaka, Bangladesh
(P-18)	I-131 Therapy for Pediatric Hyperthyroid; A Clinical Experience in Nuclear Medicine Department, Dr Hasan Sadikin Hospital, Indonesia Dr Erwin Affandi Soeriadi, Nuclear Medicine, Dr Hasan Sadikin Hospital, Indonesia
(P-19)	Quantitative Study of the Different Protocols Analysis for Excess Radiation Absorbed Doses from Radioiodine Treatment of Hyperthyroidism in Bangladesh Dr Md Nahid Hossain, Institute of Nuclear Medicine & Ultrasound, Dhaka, Bangladesh
(P-20)	Thyroid Functional Status in Chronic Kidney Disease (CKD) Dr Mosharruf Hossain, Nuclear Medicine, Rajshahi Medical College Hospital, Rajshahi, Bangladesh
(P-21)	Effect of Single Dose of Radioiodine Therapy on Volume Reduction of Thyroid Gland in Hyperthyroidism Dr Shamrukh Khan, Institute of Nuclear Medicine & Ultrasound, Dhaka, Bangladesh
(P-22)	Graded Empirical I-131 Therapy in Differentiated Thyroid Cancer – Is There an Ideal Dose? Dr Ajit Shinto, Nuclear Medicine and PET, KMCH, Coimbatore, India
(P-23)	Role of Tc-99m Pertechnetate Thyroid Scintigraphy in Detecting Etiology of Congenital Hypothyroidism Dr Aulia Huda Buchori, Dr Hasan Sadikin Hospital / Padjadjaran University, Bandung, Indonesia
(P-24)	Incremental Value of 131I-SPECT/CT Fusion Imaging Over 131I-WBS in the Management of Patients with Differentiated Thyroid Carcinoma Dr Ye Zhi-Yi, Nuclear Medicine, Xinhua Hospital, Shanghai Jiaotong University, Shanghai, China
(P-25)	Empirical Dual Dose Iodine-131 Therapy for Graves' Disease Dr Khalid Makhdomi, Radiology, Aga Khan University Hospital, Nairobi, Kenya

4th International Conference on Radiopharmaceutical Therapy (ICRT 2011)

In Conjunction with 10th AGM of Asian Regional Cooperative Council for Nuclear Medicine (ARCCNM)

28 Nov – 2 Dec 2011

New World Saigon Hotel, Ho Chi Minh City, Vietnam

DAY 2: TUESDAY, 29 NOVEMBER 2011 (CONT'D)

(P-26)	Complications to the Mother and Child with Thyroid Cancer after the Treatment with I-131 Prof Sassan Saber, Nuclear Medicine, Shariati Hospital, Tehran, Iran
(P-27)	Lacrimal Duct Obstruction after Iodine-131 Therapy in Patients with Differentiated Thyroid Cancer Prof Abbas Takavar, Nuclear Medicine, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran
(P-28)	Comparison of Different Techniques for Assessment of Thyroid Functional Status in Patients with Hyperthyroidism Dr Qaisar Siraj, Nuclear Medicine, Farwania Hospital Kuwait, Kuwait
(P-29)	The Advantages of Routine Radiothyroablation in Well Differentiated Thyroid Carcinoma Patients Dr Hapsari Indrawati, Nuclear Medicine, Dr Hasan Sadikin Hospital, Bandung, Indonesia
(P-30)	Electrolyte Imbalance in Patients During Radioablation Na I-131 Dr Aulia Huda Buchori, Nuclear Medicine, Dr Hasan Sadikin Hospital / Padjadjaran University, Bandung, Indonesia
(P-31)	Theurapeutical Response Evaluation on Hyperthyroidism Using a Fixed Dosed of I-131 Dr Yulia Kurniawati Burhanuddin, Nuclear Medicine, Dr Hasan Sadikin Hospital, Bandung, Indonesia
(P-32)	Influence of Metastases Characteristic to Survival Rate in Papillary Thyroid Carcinoma Dr Nopriwan Agamawan Salam, Nuclear Medicine, Dr Hasan Sadikin Hospital, Bandung, Indonesia
(P-33)	Pattern of Lung Metastases and its Influence to DTC Treatment Outcome Dr Gani Gunawan, Nuclear Medicine, Dr Hasan Sadikin Hospital, Bandung, Indonesia
(P-34)	Assessment of Organification Defect in Thyroid Gland in Children with Goitrous Hypothyroidism Dr Anirudhan Narasimhan, Nuclear Medicine, G.K.N.M Hospital, Coimbatore, India
(P-35)	Nal-131 Radio Ablation for Well Differentiated Thyroid Cancer at Dr Hasan Sadikin General Hospital Dr Dodi Nugraha, Nuclear Medicine, Dr Hasan Sadikin Hospital, Bandung, Indonesia
(P-36)	Significance of Raised Anti Thyroglobulin Antibody Levels in Diffrentiated Thyroid Cancer Patients Dr Javaid Irfan, Nuclear Medicine Oncology and Radiotherapy Institute (NORI), Islamabad, Pakistan
(P-37)	Rare Case of Metastasis to Pituitary from Follicular Thyroid Carcinoma Dr Butch Magsombol, Nuclear Medicine and PET, Singapore General Hospital, Singapore
(P-38)	Efficacy of I-131 Therapy in the Treatment of Differentiated Thyroid Carcinoma: Results in 655 Patients Treated at the Nuclear Medicine Department of Bach Mai Hospital, Hanoi Prof Mai Trong Khoa, Nuclear Medicine, Bach Mai Hospital, Hanoi, Vietnam Dr Trang Ngo, Nuclear Medicine, Bach Mai Hospital, Hanoi, Vietnam
(P-39)	Radionuclide Therapy in Russia. A Status Report from the Largest Radionuclide Therapy Centre in Russia Prof Valeriy Krylov, Radionuclide Therapy Department, Medical Radiological Research Center, Obninsk, Russia
1100 – 1240	SCIENTIFIC SESSION 2: THYROID II Ben Thanh Hall, Level 1
	Session Chairpersons: 1. Dr Nguyen Thi Bich Dao, Vietnam 2. Prof Leszek Krolicki, Nuclear Medicine, Medical University of Warsaw, Poland
1100 – 1120 (O-15)	Radioiodine Therapy of Differentiated Thyroid Cancer: A Review Dr Savvas Frangos, Nuclear Medicine, Bank of Cyprus Oncology Center, Strovolos, Nicosia, Cyprus
1120 – 1140 (O-16)	Guidelines for Treatment of Differentiated Thyroid Carcinoma: A Critical Appraisal Prof Jasna Mihailovic, Nuclear Medicine, Oncology Institute of Vojvodina, Sremska Kamenica, Serbia
1140 – 1200 (O-17)	Radioiodine Treatment of Hyperthyroidism: A Review Dr Emerita Barrenechea, Nuclear Medicine, Veterans Memorial Medical Centre, Quezon City, Philippines
1200 – 1220 (O-18)	Graves' Ophthalmopathy Dr Wong Wai Yin, Nuclear Medicine, Singapore General Hospital, Singapore
1220 – 1240 (O-19)	Thyromomics Dr A Velumani, Thyrocare Technologies Ltd, Turbhe, Navi Mumbai, India

4th International Conference on Radiopharmaceutical Therapy (ICRT 2011)

In Conjunction with 10th AGM of Asian Regional Cooperative Council for Nuclear Medicine (ARCCNM)

28 Nov – 2 Dec 2011

New World Saigon Hotel, Ho Chi Minh City, Vietnam

DAY 2: TUESDAY, 29 NOVEMBER 2011 (CONT'D)

1240 – 1300	ORAL PRESENTATIONS	Ben Thanh Hall, Level 1
1240 – 1250 (O-20)	The Assessment of Oxidative Stress and Hematological Changes in Patients with Differentiated Thyroid Carcinoma Treated with Radioiodine Prof Milovan Matovic, Nuclear Medicine, Clinical Centre Kragujevac, Kragujevac, Serbia	
1250 – 1300 (O-21)	Relationship Between Radiation Absorbed Dose to the Blood and Successful Ablative Treatment in Thyroid Cancer Patients Dr Shazia Fatima, Nuclear Medicine, Oncology & Radiotherapy Institute Islamaba, Islamabad, Pakistan	
1300 – 1400	LUNCH / TRADE EXHIBITION	
1400 – 1505	SCIENTIFIC SESSION 3: BONE PAIN & RADIOSYNOVECTOMY	Ben Thanh Hall, Level 1
	Session Chairpersons: 1. Dr Emerita Barrenechea, Nuclear Medicine, Veterans Memorial Medical Centre, Quezon City, Philippines 2. Dr Qaisar Siraj, Nuclear Medicine, Farwania Hospital Kuwait, Kuwait	
1400 – 1425 (O-22)	Radiosynovectomy in the Treatment of Arthritis Dr Knut Liepe, Nuklearmedizin, Klinikum Kassel, Germany	
1425 – 1445 (O-23)	Use of Re-188 Colloid in Radiosynovectomy: Experience at AIIMS Prof Rakesh Kumar, Nuclear Medicine & PET, All India Institute of Nuclear Medicine, India	
1445 – 1505 (O-23A)	Radiosynoviorthosis (Radiation Synovectomy): State of the Art 2011 Prof Gynter Moedder, German Centre for Radiosynoviorthosis, Cologne, Germany	
1505 – 1545	ORAL PRESENTATIONS	Ben Thanh Hall, Level 1
1505 – 1515 (O-25)	Intra-Articular Evaluation of Lu-177 Hydroxyapatite in Animal Model Dr Muhammad Sohaib, Medical Sciences, Pakistan Institute of Engineering and Applied Science (PIEAS), Islamabad, Pakistan	
1515 – 1525 (O-26)	Development of Colloidal Samarium Phosphate [32P] Injection for Radiation Synovectomy-A New Therapeutic Radiopharmaceutical Agent For The Treatment Of Joint Disorders Dr Prabhakar Ganti, Department of Atomic Energy (DAE), Board of Radiation & Isotope Technology, Navi Mumbai, India	
1525 – 1535 (O-27)	Optimal Timing of Biphosphonate Therapy in Combination with Samarium-153 Therapy in Metastatic Bone Disease Dr Nigora Rasulova, Nuclear Medicine, Republic Specialized Center of Surgery, Tashkent, Uzbekistan	
1535 – 1545 (O-28)	Evaluation of P-32 for Bone Pain Palliation in Prostate Cancer with Skeletal Metastases Dr Muhammad Aleem Khan, Nuclear Medicine, Nuclear Medicine Oncology and Radiotherapy Institute (NORI), Islamabad, Pakistan	
1545 – 1600	COFFEE / TEA / TRADE EXHIBITION	Ben Thanh Hall Foyer Pre-Function Area, Level 1
	POSTERS PRESENTATION: BONE PAIN PALLIATION / RADIOSYNOVECTOMY	Ben Thanh Hall Foyer Pre-Function Area, Level 1
	Session Coordinators: 1. Dr Vo Khac Nam, Vietnam 2. Dr Tran Song Toan, Nuclear Medicine, Cho Ray Hospital, Ho Chi Minh, Vietnam	
(P-40)	Detection of Bone Metastases by Planer Bone Scintigraphy and SPECT Bone Scintigraphy Dr MD Sayedur Rahman Miah, Centre for Nuclear Medicine & Ultrasound, Bangladesh Atomic Energy Commission, Comilla, Bangladesh	
(P-41)	Our First Experiences in Palliative Treatment of Painful Bone Metastases with Sm-153 Dr Zvezdana Rajkovic, Nuclear Medicine, Clinical Center Banja Luka, Banja Luka, Bosnia & Herzegovina	
(P-42)	Evaluation of Prostate Cancer with Serum Prostate Specific Antigen, Alkaline Phosphatase Level and Bone Scintigraphy Dr Afroz Shirin, Scintigraphy, Institute of Nuclear Medicine & Ultrasound, Dhaka, Bangladesh	

4th International Conference on Radiopharmaceutical Therapy (ICRT 2011)

In Conjunction with 10th AGM of Asian Regional Cooperative Council for Nuclear Medicine (ARCCNM)

28 Nov – 2 Dec 2011

New World Saigon Hotel, Ho Chi Minh City, Vietnam

DAY 2: TUESDAY, 29 NOVEMBER 2011

- (P-43) **Bone Scintigraphy Findings of Multiple Osteoblastic Lesions in a Child with Primitive Neuroectodermal Tumor**
Dr Karina Michaela Dela Cruz, Nuclear Medicine, University of Santo Tomas, Manila, Philippines
- (P-44) **Bone-Seeking Radiopharmaceuticals for Pain Palliation in Prostate Cancer Metastasis**
Dr Raluca Mititelu, Nuclear Medicine, Central University Military Hospital Bucharest, Bucharest, Romania
- (P-45) **Present Day Utility of Whole Body Bone Scan in Evaluating Silent Skeletal Metastases in Apparently Operable Non Small Cell Lung Cancer when PET is not Available**
Dr Ajit Shinto, Nuclear Medicine and PET, KMCH, Coimbatore, India
- (P-46) **⁸⁹Sr Bremsstrah Lung SPECT Imaging in Bone Metastases**
Dr Masanobu Ishiguro, Section of Radiology Division of Nuclear Medicine, Fujita Health University Hospital, Toyoake, Japan
- (P-47) **Comparison of the Value of 18 F-FDG PET And 99 Tcm-MDP Bone Scan in the Detection of Bone Metastases**
Dr Shuqi Wu, Nuclear Medicine, Xinhua Hospital, Shanghai Jiaotong University, Shanghai, China
- (P-48) **Current Status of Radionuclide Therapy in Indonesia**
Dr Alvita Dewi Siswoyo, Nuclear Medicine, RS Dr Hasan Sadikin, Bandung, Indonesia
- (P-49) **Effectiveness of Bone Metastases Treatment by Sm-153 Oxabifore in Combination with Monoclonal Antibody Denosumab (Xgeva)**
Dr Nigora Rasulova, Nuclear Medicine, Republic Specialized Center of Surgery, Tashkent, Uzbekistan

1600 – 1730 **SCIENTIFIC SESSION 4: RADIOPHARMACY / GENERAL NUCLEAR MEDICINE** Ben Thanh Hall, Level 1

Session Chairpersons:

1. Prof Alan Perkins, Radiological and Imaging Sciences, Nottingham University Hospital, Nottingham, United Kingdom,
2. Prof Azu Owunwanne, Nuclear Medicine, Faculty of Medicine, Kuwait University, Safat, Kuwait

1600 – 1625 **Theragnostic Radiopharmaceuticals: An Emerging Paradigm Empowering Personalized Medicine**
(O-29) Dr Suresh Srivastava, Collider-Accelerator Department, Brookhaven National Laboratory, Upton, NY USA

1625 – 1640 **ONCIDIUM Foundation: A Perspective**
(O-30) Dr Richard Zimmermann, IBA, Molecular, IBA, Louvain-La-Neuve, Belgium

1640 – 1700 **Regulatory Aspects of Therapeutic Radiopharmaceuticals**
(O-31) Dr Maung Maung Saw, Clinical Imaging Research Centre, National University of Singapore, Singapore

1700 – 1720 **Clinical Applications of SPECT/CT in Oncology**
(O-32) Dr Sonia Sergieva, Nuclear Medicine, Sofia Cancer Centre, Sofia, Bulgaria

1720 – 1800 **Radiopharmaceutical And Molecular Therapy Quiz
(Three Prizes for 3 Participants Scoring Highest Scores)**
(O-33) Dr Gopinath Gnanasegaran, Nuclear Medicine, Guys & St Thomas' Hospital NHS Foundation Trust, St Thomas Hospital, London, United Kingdom

1900 – 2300 **FORMAL INAUGURATION OF THE CONFERENCE & GALA DINNER** Grand Mekong Ballroom, Level 1

2300 **END OF DAY 2**

4th International Conference on Radiopharmaceutical Therapy (ICRT 2011)

In Conjunction with 10th AGM of Asian Regional Cooperative Council for Nuclear Medicine (ARCCNM)

28 Nov – 2 Dec 2011

New World Saigon Hotel, Ho Chi Minh City, Vietnam

DAY 3: WEDNESDAY, 30 NOVEMBER 2011

0800 – 1020 **SCIENTIFIC SESSION 5: GI TRACT CANCER / LIVER CANCER** Ben Thanh Hall, Level 1

Session Chairpersons:

1. Dr Patricia Bernal Trujillo, Fundacion Santa Fe, Bogota, Colombia
2. Prof Harvey Turner, University of Western Australia, Fremantle Hospital, Australia

0800 – 0825 **Targeted Chemoradiation in Metastatic Colorectal Cancer: A Phase I Trial of 131I-Hua33 with Concurrent Capecitabine**
(O-34)

Prof Andrew Scott, Centre for PET, Austin Hospital, Heidelberg, Australia

0825 – 0850 **Targeted Radionuclide Therapy of Liver Tumors**
(O-35)

Prof Gregory Wiseman, Radiology, Mayo Clinic, Rochester, USA

0850 – 0915 **Radiological and Clinical Efficacy of Radio-embolization (Re) Using 188Re HSA-microspheres in Patients with Advanced, Primary or Metastatic Liver Cancer**
(O-36)

Dr Jaroslaw Cwikla, Radiology and Diagnostic Imaging, Postgraduate Medical Centre and Central Clinical Hospital, Warsaw, Poland

0915 – 0935 **PET is Superior to CT in Assessing Response to SIRT in Liver Tumours**
(O-37)

Prof Adil Al-Nahhas, Nuclear Medicine, Imperial College, London, United Kingdom

0935 – 0955 **Molecular Radiotherapy in the UK: The Current Status**
(O-38)

Prof John Buscombe, Nuclear Medicine, Royal Free Hospital, Cambridge, United Kingdom

0955 – 1020 **Statistics – OR, RR and HR**
(O-39)

Prof Janez Stare, Faculty of Medicine, University of Ljubljana, Slovenia

1020 – 1030 **ORAL PRESENTATIONS** Ben Thanh Hall, Level 1

1020 – 1030 **Does Clinical Outcome In Hepatic Y-90 Microsphere Therapy Depends On Correlation Between Y-90 and Tc-99m MAA Distributions?**
(O-40)

Dr Karin Knesaurek, Radiology / Nuclear Medicine, Mount Sinai Medical Center, New York, USA

1030 – 1100 **COFFEE / TEA / TRADE EXHIBITION** Ben Thanh Hall Foyer
Pre-Function Area, Level 1

1030 – 1100 **POSTER PRESENTATIONS: MOLECULAR IMAGING, RADIOPHARMACY** Ben Thanh Hall Foyer
Pre-Function Area, Level 1

Session Coordinators:

1. Dr Butch Magsombol, Nuclear Medicine and PET, Singapore General Hospital, Singapore
2. Dr Nigora Rasulova, Nuclear Medicine, Republic Specialized Center of Surgery, Tashkent, Uzbekistan

(P-50) **Normal Uptake Value of C-11 Acetate in Some Organs**

Dr Thi Minh Chau Trinh, Nuclear Medicine, University Medical Center, Ho Chi Minh City, Vietnam

(P-51) **Development of Nanoradiopharmaceuticals**

Dr Ralph Santos-Oliveira, Laboratory of Nanoradiopharmaceuticals, University Hospital Clementino Fraga Filho, Rio de Janeiro, Brazil

(P-52) **Nanoradiopharmaceuticals: Development of Labeling Process**

Dr Ralph Santos-Oliveira, Laboratory of Nanoradiopharmaceuticals, University Hospital Clementino Fraga Filho, Rio de Janeiro, Brazil

(P-53) **Synthesis, Radio Labeling and Biological Evaluation of [67Ga]- 5,10,15,20-Tetrakis(Pentafluorophenyl) Porphyrin Complexes as an Imaging Agent**

Dr Mohammad Reza Aboudzadeh Rovais, Nuclear Medicine Research Group, Agricultural, Medical and Industrial Research School, Karaj, Iran

(P-54) **Synthesis, Radiolabeling and Biological Evaluation of [111In]-Maltolate Complex as an Imaging Agent**

Prof Yousef Fazaeli, Nuclear Medicine Research Group, Agricultural, Medical and Industrial Research School (AMIR), Karaj, Iran

(P-55) **Production, Quality Control and Imaging of 64Cu-ATSM in Healthy Rabbits for Clinical Applications**

Prof Yousef Fazaeli, Nuclear Medicine Research Group, Agricultural, Medical and Industrial Research School (AMIR), Karaj, Iran

4th International Conference on Radiopharmaceutical Therapy (ICRT 2011)

In Conjunction with 10th AGM of Asian Regional Cooperative Council for Nuclear Medicine (ARCCNM)

28 Nov – 2 Dec 2011

New World Saigon Hotel, Ho Chi Minh City, Vietnam

DAY 3: WEDNESDAY, 30 NOVEMBER 2011 (CONT'D)

- (P-56) **Synthesis, Radiolabeling and Biological Evaluation of [67Ga]-Maltolate Complex as an Imaging Agent**
Prof Yousef Fazaeli, Nuclear Medicine Research Group, Agricultural, Medical and Industrial Research School (AMIR), Karaj, Iran
-
- (P-57) **Preparation and Evaluation of [67Ga]-Tetra Phenyl Porphyrin Complexes as Imaging Agents**
Prof Yousef Fazaeli, Nuclear Medicine Research Group, Agricultural, Medical and Industrial Research School (AMIR), Karaj, Iran
-
- (P-58) **Radiosynthesis and Biological Evaluation of [111In]-5,10,15,20-Tetrakis(Pentafluorophenyl) Porphyrin Complex as a Possible Imaging Agent**
Dr Mohammad Reza Aboudzadeh Rovais, Nuclear Medicine Research Group, Agricultural, Medical And Industrial Research School, Karaj, Iran
-
- (P-59) **Emergency Handling in a Medical Cyclotron Facility**
Dr Rajeev Kumar, PET Scan Centre, Medical Cyclotron Facility, Army Hospital Research And Referral, New Delhi, India
-
- (P-60) **Development and Evaluation of New Protocol for Synthesis of 6-(18F) Fluoro-L-DOPA**
Dr Rajeev Kumar, PET Scan Centre, Medical Cyclotron Facility, Army Hospital Research And Referral, New Delhi, India
-
- (P-61) **AFP-Combined 18F-FDG PET/CT Detection of HCC and its Recurrence**
Dr Wu Shuqi, Nuclear Medicine, Xinhua Hospital, Shanghai Jiaotong University, Shanghai, China
-
- (P-62) **Simple, Reliable and Cost Effective Radiochemical Purity Test Technique for N-13 Ammonia**
Dr Dhananjay Kumar Singh, Nuclear Medicine, Army Hospital Research And Referral, New Delhi, India
-
- (P-63) **99mTc-Doxorubicin Labeling and its Pre-Clinical Evaluation as a Potential Scintigraphic Probe For Tumor Imaging**
Dr Baljinder Singh, Nuclear Medicine, PGIMER, Chandigarh, India
-
- (P-64) **Engineering Salmonella Typhimurium to Become a Dual Purpose-Probe for Therapeutic and in Vivo Monitoring Applied in Cancer or Myocardial Infarction**
Dr Vu Hong Nguyen, Nuclear Medicine, CNU Hwasun Hospital, Hwasun, South Korea
-
- (P-65) **Preliminary Results of Various Pegylated I-RGD Peptides for Animal PET-Imaging**
Prof Apo Ahonen, Physiology And Nuclear Medicine, HUSLAB/HUCH, Helsinki, Finland
-
- (P-66) **Medical Cyclotron: Accidental Scenarios and Analysis**
Dr Nguyen Tan Chau, Unit of PET-CT & Cyclotron, Cho Ray Hospital, Ho Chi Minh, Vietnam
-
- (P-67) **To Establish a Synthesis Protocol of 68Gallium-DOTANOC Using 0.05MHCl as Eluant of 68Ge/68Ga Generator for PET Imaging of Neuroendocrine Tumors (NETS)**
Dr Snehlata Lata, Nuclear Medicine & PET, All Institute of Medical Sciences, New Delhi, India
-
- (P-68) **Production of Radiopharmaceutical F-18 FDG and C-11 Acetate Using Cyclotron 11 Mev at Cho Ray Hospital**
Dr Truong Ka My Dang, PET-CT & Cyclotron, Cho Ray Hospital, Ho Chi Minh, Vietnam
-
- (P-69) **Radionuclide Imaging for Neuroendocrine Tumours: Experience of Singapore General Hospital (SGH), The Largest Acute Tertiary Hospital in Singapore**
Dr Thang Sue Ping, Nuclear Medicine and PET, Singapore General Hospital, Singapore
-
- (P-70) **Cyclotron Production of 99mTc in Canada**
Dr Erik Van Lier, Targetry and Radiochemistry, Advanced Cyclotron Systems Inc, Richmond, Canada
-
- (P-71) **Diagnosis of Pulmonary Neuroendocrine Tumors with 99mTc-Tectrotide (99mTc-HYNIC –TOC) SPECT/CT and 18F-FDG PET-CT in the Selection of the First Line of Treatment and Determining Staging and Restaging**
Dr Norbert Szalus, Nuclear Medicine, Military Institute of Medicine, Warsaw, Polska
-
- (P-71A) **Peptide Receptor Radionuclide Therapy (PRRT): Colombia Experience**
Dr Patricia Bernal Trujillo, Nuclear Medicine, Fundacion Santa fe de Bogota, Bogota, Colombia

4th International Conference on Radiopharmaceutical Therapy (ICRT 2011)

In Conjunction with 10th AGM of Asian Regional Cooperative Council for Nuclear Medicine (ARCCNM)

28 Nov – 2 Dec 2011

New World Saigon Hotel, Ho Chi Minh City, Vietnam

DAY 3: WEDNESDAY, 30 NOVEMBER 2011 (CONT'D)

1100 – 1230 **SCIENTIFIC SESSION 6: NEUROENDOCRINE TUMORS I** Ben Thanh Hall, Level 1

Session Chairpersons:

1. Prof John Buscombe, Nuclear Medicine, Royal Free Hospital, Cambridge, UK
2. Prof Andrew Scott, Centre For PET, Austin Hospital, Heidelberg, Australia

1100 – 1125 **Peptide Receptor Radionuclide Therapy – The Innsbruck Experience**
(O-41) Prof Irene Virgolini, Nuclear Medicine & PET, Medical University Of Innsbruck, Innsbruck, Austria

1125 – 1150 **Peptide Receptor Radionuclide Therapy of Neuroendocrine Tumors – The Bad Berka Experience After 10 Years in Over 1000 Patients**
(O-42) Prof Richard Baum, Department of Nuclear Medicine, Center for PET/CT, Bad Berka, Germany

1150 – 1205 **PRRT-Experience at Jaslok Hospital**
(O-43) Dr Vikram Lele, Department of Nuclear Medicine & PET-CT, Jaslok Hospital & Research Centre, Mumbai, India

1205 – 1220 **Ga-68 DOTATATE Imaging & PRRT in South Africa**
(O-44) Dr Carlos D Libhaber, Nuclear Cardiology, University of the Witwaterstrand, Johannesburg, South Africa

1220 – 1235 **New DOTA-Based Bisphosphonate Ligands for PET/CT and Endoradiotherapy of Bone Metastases**
(O-24) Dr Achim Reibel, University of Mainz, Institute of Nuclear Chemistry, Mainz, Germany

1235 – 1300 **ORAL PRESENTATIONS** Ben Thanh Hall, Level 1

1235 – 1245 **90Y And 177Lu – Radionuclides for Peptide Receptor Radionuclide Therapy**
(O-45) Dr Dariusz Pawlak, Research and Development, Institute of Atomic Energy POLATOM, Otwock, Poland

1245 – 1255 **Early Prediction of Tumor Response in GEP NET by the Sequential Change of Absorbed Doses During Treatment with Lu177-Octreotate**
(O-46) Dr Ezziddin Samer, MD, Nuclear Medicine, University Bonn, Bonn, Germany

1255 – 1305 **Effect of Peptide Receptor Radionuclide Therapy (PRRT) with Tandem Isotopes- 90Y/ 177Lu-DOTATATE in Patients with Disseminated Neuroendocrine Tumors Depending on Qualification PET/CT with 18FDG**
(O-47) Dr Jolanta Kunikowska, Medical University Of Warsaw, Nuclear Medicine Department, Medical University Of Warsaw, Warsaw, Poland

1305 – 1400 **LUNCH / TRADE EXIBITION**

1400 – 1510 **SCIENTIFIC SESSION 7: NEUROENDOCRINE TUMORS II** Ben Thanh Hall, Level 1

Session Chairperson:

1. Prof Sobhan Vinjamuri, Nuclear Medicine, Royal Liverpool University Hospital, Liverpool, United Kingdom
2. Dr Cornelis Hoefnagel, Division of Diagnostic Oncology, The Netherlands Cancer Institute, The Netherlands

1400 – 1425 **Combined Modality Radiopeptide Therapy of Neuroendocrine Tumours**
(O-48) Prof Harvey Turner, University Of Western Australia, Fremantle Hospital, Australia

1425 – 1450 **PRRT: The Italian Experience**
(O-49) Prof Giovanni Paganelli, Divisione Di Medicina Nucleare, IEO Istituto Europeo Di Oncologia, Milano, Italy

1450 – 1510 **Meta-Analysis of Radionuclide Therapy in NETs**
(O-50) Dr Shaunak Navalkissoor, Nuclear Medicine, Royal Free Hospital NHS Trust, London, United Kingdom

1510 – 1530 **ORAL PRESENTATIONS** Ben Thanh Hall, Level 1

1520 – 1530 **Tc-Carbonyl Based Octreotide Derivatives**
(O-51) Dr Guhlke Stefan, Nuclear Medicine, University of Bonn, Bonn, Germany

4th International Conference on Radiopharmaceutical Therapy (ICRT 2011)

In Conjunction with 10th AGM of Asian Regional Cooperative Council for Nuclear Medicine (ARCCNM)

28 Nov – 2 Dec 2011

New World Saigon Hotel, Ho Chi Minh City, Vietnam

DAY 3: WEDNESDAY, 30 NOVEMBER 2011 (CONT'D)

1530 – 1600

**POSTERS PRESENTATIONS:
GENERAL NUCLEAR MEDICINE & MISCELLANEOUS (ARCCNM)**

Ben Thanh Hall Foyer
Pre-Function Area, Level 1

Session Coordinators:

1. Dr Marika Vereb, Nuclear Medicine Department, Klinikum Kassel, Kassel, Germany
2. Ms Nguyen Thi Kim Dung, Vietnam

- (P-72) **Gamma Camera Based GFR Measurement as an Alternative to 24 Hours Urinary Creatinine Clearance in Healthy Kidney Donors**
Dr Tania Ahmed Ahmed, Nuclear Medicine & Ultrasound, Centre For Nuclear Medicine & Ultrasound, Chittagong, Chittagong, Bangladesh
- (P-73) **Differences in Decline in GFR with Age Between Males and Females. Reference Data on 24 Hours Urinary Creatinine Clearance and DTPA Clearance**
Dr Tania Ahmed Ahmed, Nuclear Medicine & Ultrasound, Centre For Nuclear Medicine & Ultrasound, Chittagong, Chittagong, Bangladesh
- (P-74) **Preparation and Bio Distribution of 99mtechnetium-Annexin V for In Vivo Detection of Apoptosis**
Dr Saeed Rajabifar, Nuclear Medicine, AMIRS, Karaj, Iran
- (P-75) **Ciprofloxacin Labeling by 99mtechnetium and its Bio Distribution in Normal and Infected Animals**
Dr Saeed Rajabifar, Nuclear Medicine, AMIRS, Karaj, Iran
- (P-76) **Production and Quality Control of 99mtechnetium-Igg-Hynic for Infection Imaging in Experimental Rats**
Dr Saeed Rajabifar, Nuclear Medicine, AMIRS, Karaj, Iran
- (P-77) **Diagnosing Multifocal Tuberculosis in Children with Tc-99m Ethambutol Scintigraphy: A Case Report**
Dr Alvita Dewi Siswoyo, Nuclear Medicine, RS Dr Hasan Sadikin, Bandung, Indonesia
- (P-78) **A Comparative Study of Dobutamine Stress Myocardial Perfusion Imaging and Dobutamine Stress Echocardiography in the Detection of Coronary Artery Disease in Female Patient – Initial Experience**
Dr Nasreen Sultana Nasreen, Nuclear Medicine, Institute of Nuclear Medicine And Ultrasound, BSMMU Campus Block, Dhaka, Bangladesh
- (P-79) **I-131 Meta-Iodobenzylguanidine and Tc99m Sestamibi Parathyroid SPECT Scintigraphy in Diagnosis of Multiple Endocrine Neoplasia 2A Syndrome**
Dr Jamilla Gomez, Nuclear Medicine, St Lukes Hospital, Quezon City, Philippines
- (P-80) **Myocardial Perfusion Imaging and Calcium Scoring as Coronary Artery Disease Predictors**
Dr Jamilla Gomez, Nuclear Medicine, St Lukes Hospital, Quezon City, Philippines
- (P-81) **Comparison of Tc-99m Ethambutol Scintigraphy and Scoring System in Diagnosing Pediatric Tuberculosis**
Dr Ivana Dewi Mulyanto, Department of Nuclear Medicine, Universitas Padjadjaran/RS Hasan Sadikin, Bandung, Indonesia
- (P-82) **Clinical Utility of F-18 FDG PET/CT & Tc-99m MDP Bone Scintigraphy in Ewing's Sarcoma and Other Sarcomaas**
Dr Judy Nguyen, Nuclear Medicine, Stanford University Medical Center, Stanford, USA
- (P-83) **Castleman's Disease on 18FDG PET-CT**
Dr Jamilla Gomez, Nuclear Medicine, St Lukes Hospital, Quezon City, Philippines
- (P-84) **Correlation Between Bone Scintigraphy and Tumour Markers in Patients with Breast Cancer**
Dr Mohshi Um Mokaddema, Nuclear Medicine, Institute of Nuclear Medicine and Ultrasound, Dhaka, Bangladesh
- (P-85) **Impact of F-18 FDG PET/CT in Staging of Carcinoma Cervix**
Dr Zaheer Chirag, Nuclear Medicine, BINO Cancer Hospital, Bahawalpur, Pakistan
- (P-86) **Clinical Implications of PSA Level & Gleason Score in Predicting Possible Metastatic Bone Disease in Patients of Carcinoma Prostate**
Dr Zaheer Chirag, Nuclear Medicine, BINO Cancer Hospital, Bahawalpur, Pakistan

4th International Conference on Radiopharmaceutical Therapy (ICRT 2011)

In Conjunction with 10th AGM of Asian Regional Cooperative Council for Nuclear Medicine (ARCCNM)

28 Nov – 2 Dec 2011

New World Saigon Hotel, Ho Chi Minh City, Vietnam

DAY 3: WEDNESDAY, 30 NOVEMBER 2011 (CONT'D)

- (P-87) **Role of FDG PET/CT in Diagnostic Evaluation of Carcinoma Urinary Bladder: Comparison with CT**
Dr Dhritiman Chakraborty, Department of Nuclear and Experimental Medicine, IPGME & R, Kolkata, Kolkata, India
- (P-88) **Role of Tc99m MIBI Lower Limb Muscle Perfusion SPECT: In Diagnosis and Follow Up of Peripheral Arterial Diseases (PAD)**
Dr Rashid Rasheed, Nuclar Medicine, GINUM, Gujranwala, Pakistan
- (P-89) **Carotid Intima-Media Thickness (CIMT) as a Predictor of Hemodynamically Significant Coronary Artery Disease (CAD) Detected by Myocardial Perfusion Imaging (MPI)**
Dr Tapati Mandal, Nuclear Medicine, Institute Of Nuclear Medicine And Ultrasound, Dhaka, Bangladesh
- (P-90) **Hepatobiliary Scintigraphy in the Non-Invasive Assessment of Early Hepatic Dysfunction in Patients with Risk Factor for Metabolic Syndrome**
Dr Ajit Shinto, Nuclear Medicine and PET, KMCH, Coimbatore, India
- (P-91) **Tc 99m HIDA Diagnoses Early Hepatic Dysfunction in Type II Diabetics**
Dr Ajit Shinto, Nuclear Medicine and PET, KMCH, Coimbatore, India
- (P-92) **Early and Delayed F-18 FDG PET in Assessment of Disease Activity in Tuberculosis**
Dr Ajit Shinto, Nuclear Medicine and PET, KMCH, Coimbatore, India
- (P-93) **Vision of Nuclear Medicine in Bangladesh – A Road Map**
Prof Mizanul Hasan, Nuclear Medicine, Institute Of Nuclear Medicine & Ultrasound, BSMMU, Dhaka, Bangladesh
- (P-94) **Technetium-99m-Sestamibi Scintigraphy on Patient with Nasopharyngeal Carcinoma and Lymphadenopathy Tuberculosis: A Case Report**
Dr Yulia Kurniawati Burhanuddin, Nuclear Medicine, Hasan Sadikin Hospital, Bandung, Indonesia
- (P-95) **Evaluation of Low Grade Gliomas Using F-18 FDOPA and F-18 FDG PET/CT**
Dr Abhinav Jaimini, Department of Clinical PET, Institute of Nuclear Medicine and Allied Sciences, Delhi, India
- (P-96) **Case Report: Tc-99m-Ethambuthol Uptake in Case of Leprosy**
Dr Andika Hananto Gunawan, Department Of Nuclear Medicine, Hasan Sadikin Hospital / Univesitas Padjadjaran, Bandung, Indonesia
- (P-97) **Role of Tc-99m Ethambutol Scintigraphy in Diagnosing Tuberculosis in Children with Scoring Systems as Diagnostic Approach**
Dr Alvita Dewi Siswoyo, Nuclear Medicine, Rs Dr. Hasan Sadikin, Bandung, Indonesia
- (P-98) **Role of Dobutamine Stress Myocardial Perfusion Imaging (DS MPI) for the Detection of Myocardial Viability (MV) in Significantly Stenosed Coronary Artery Disease (CAD)**
Dr Sarwat Ara Sultana Khandaker, Nuclear Medicine, Institute Of Nuclear Medicine & Ultrasound, Dhaka, Bangladesh
- (P-99) **Optimization of SPECT MPI Using a Prototype Dynamic Heart Phantom**
Dr Ourania Demetriadou, Nuclear Medicine, Limassol General Hospital, Limassol, Cyprus
- (P-100) **Outcome of Patients with Positive Exercise Test and Normal Exercise Myocardial Perfusion SPECT**
A/Prof Faria Nasreen, Nuclear Medicine, Institute Of Nuclear Medicine & Ultrasound, Dhaka, Bangladesh
- (P-101) **Usefulness Of Dacryoscintigraphy in the Management of Patients with Epiphora**
Dr Madhur Kumar Srivastava, Nuclear Medicine, Apollo Hospitals, Chennai, India

4th International Conference on Radiopharmaceutical Therapy (ICRT 2011)

In Conjunction with 10th AGM of Asian Regional Cooperative Council for Nuclear Medicine (ARCCNM)

28 Nov – 2 Dec 2011

New World Saigon Hotel, Ho Chi Minh City, Vietnam

DAY 3: WEDNESDAY, 30 NOVEMBER 2011 (CONT'D)

- (P-102) **Noninvasive Rest and Acetazolamide 99mTc-HM-PAO Brain Perfusion SPECT Imaging with One Day Protocol Using SPECT/CT System**
Dr Dang An Binh, Nuclear Medicine, Cho Ray Hospital, Ho Chi Minh, Vietnam
- (P-103) **Differentiating Benign and Malignant Lesions of Uterus by FDG and FES PET Imaging**
Dr Raihan Hussain, Thyroid Division, Institute of Nuclear Medicine and Ultrasound, Dhaka, Bangladesh
- (P-104) **Illustration of a Single Anomalous Coronary Artery with Myocardial Ischemia by Fusion of N-13 Ammonia PET/CT with CT Coronary Angiography – Case Report**
Prof Bom Hee-Seung Henry, Nuclear Medicine, CNU Medical School, Hwasun, S. Korea
- (P-105) **Comparative Study of Exercise Tolerance Test (ETT) and SPECT-Myocardial Perfusion Imaging (MPI) in the Diagnosis of Coronary Artery Disease in Bangladeshi Women**
Dr Akhter Nahid, Nuclear Medicine, Centre For Nuclear Medicine & Ultrasound, Dinajpur, Dhaka, Bangladesh
- (P-106) **Radiation Exposure of Patients Undergoing Whole-Body Dual-Modality 18F-FDG PET/CT Examinations at Choray Hospital – Vietnam**
Dr Le Tran Tuan Kiet, Radiation Safety, Cho Ray Hospital, Ho Chi Minh, Vietnam
- (P-107) **The Role of 99mTc-MIBI Pinhole Scintigraphy in Preoperative Parathyroid Localization in Era of SPECT/CT**
Dr Lucia Kaliska, Nuclear Medicine, Institute Of Nuclear Medicine & Molecular Medicine, Banska Bystrica, Slovakia
- (P-108) **Langerhans Cell Histiocytosis. Imaging Findings and Utility of FDG PET/CT in an Adult Patient with Multi-Organ Involvement**
Dr Xie Wanying, Nuclear Medicine, Singapore General Hospital, Singapore
- (P-109) **Juxtapapillary Dieulafoy Lesion: An Obscure Case of G.I. Bleeding Localized Using Tc-99m RBC Scintigraphy**
Dr Millicent Grace De Guzman, Nuclear Medicine, University of Santo Tomas Hospital, Manila, Philippines
- (P-110) **Utility of Delayed Imaging in Evaluating Common Bile Duct Obstruction with Tc-99m Mebrofenin Hepatobiliary Scanning**
Dr Nand Relan, Radiology, Stony Brook University Medical Center, Stony Brook, USA
- (P-111) **Role of 18F-Fluoro-Deoxyglucose Positron Emission Tomography/Computed Tomography Fusion Imaging (18F-FDG PET/CT) for Preoperative Axillary Staging in Primary Breast Cancer: A Prospective Analysis**
Dr Ankur Pruthi, Department of Nuclear Medicine, Rajiv Gandhi Cancer Institute and Research Centre, New Delhi, India
- (P-112) **Role of FDG in Primary Lesion Identification (A Preliminary Result)**
Dr Hendra Budiawan, Nuclear Medicine, MRCCC - Siloam Hospitals, Jakarta Indonesia
- (P-113) **PET/CT and Contrast Enhanced CT in the Detection of Malignant Lesions: A Prospective Study**
Dr Susan Gironella-Camomot, Nuclear Medicine, Cagayan de Oro Medical Center, Cagayan de Oro City, Philippines

1600 – 1630

SCIENTIFIC SESSION 8: EDUCATION & TRAINING, MOLECULAR IMAGING

Ben Thanh Hall, Level 1

Session Chairpersons:

1. Prof Lee Jae-Tae, Nuclear Medicine, Kyungpook National University Hospital, Daegu, Korea
2. Prof Jun Hatazawa, Japan

1600 – 1630

Training Nuclear Medicine Physicians Foundation and Ideal Model

(O-52)

Prof Abdelhamid Elgazzar, Nuclear Medicine & PET, Medicine University of Kuwait, Kuwait

4th International Conference on Radiopharmaceutical Therapy (ICRT 2011)

In Conjunction with 10th AGM of Asian Regional Cooperative Council for Nuclear Medicine (ARCCNM)

28 Nov – 2 Dec 2011

New World Saigon Hotel, Ho Chi Minh City, Vietnam

DAY 3: WEDNESDAY, 30 NOVEMBER 2011 (CONT'D)

1630 – 1710	ORAL PRESENTATIONS (ARCCNM)	Ben Thanh Hall, Level 1
1630 – 1640 (O-53)	Detection of Activated Microglia with Translocator Protein (18 Kda) Ligand, [18F]FEPPA PET Prof Hiroshi Toyama, Radiology, Fujita Health University, Toyoake, Japan	
1640 – 1650 (O-54)	FDG Uptake, Glucose Transporter Type-1 and KI-67 Expressions Dr Xuan Canh Nguyen, Unit Of Pet/Ct And Cyclotron, Cho Ray Hospital, Ho Chi Minh, Vietnam	
1650 – 1700 (O-55)	Early Response Assessment in Gastrointestinal Stromal Tumors with FDG PET Scan 24 Hours after a Single Dose of Imatinib Dr Ajit Shinto, Nuclear Medicine and PET, KMCH, Coimbatore, India	
1710 – 1800	ARCCNM NATIONAL DELEGATES' ASSEMBLY	To Be Advised
1745 – 1900	WARMTH MEMBERS' ASSEMBLY ALL MEMBERS OF WARMTH TO ATTEND THE MEETING	Ben Thanh Hall, Level 1
1930 – 2300	DINNER & 10 YEARS OF ARCCNM CELEBRATION	Grand Mekong Ballroom, Level 1
2300	END OF DAY 3	

4th International Conference on Radiopharmaceutical Therapy (ICRT 2011)

In Conjunction with 10th AGM of Asian Regional Cooperative Council for Nuclear Medicine (ARCCNM)

28 Nov – 2 Dec 2011

New World Saigon Hotel, Ho Chi Minh City, Vietnam

DAY 4: THURSDAY, 1 DECEMBER 2011

0800 – 1030 **SCIENTIFIC SESSION 9: DOSIMETRY, MOLECULAR IMAGING, GENERAL** Ben Thanh Hall, Level 1

Session Chairpersons:

1. Prof Lee Myung Chul, Nuclear Medicine, Seoul National University, Seoul, Korea
2. Dr Pankaj Dougall, Nuclear Medicine Services, Nuclear Medicine And PET-CT, Max Super Speciality Hospitals, New Delhi, India

0800 – 0825 **Usefulness of SPECT/CT for Radionuclide Therapy**
(O-56) Dr Cornelis Hoefnagel, Division of Diagnostic Oncology, The Netherlands Cancer Institute, The Netherlands

0825 – 0850 **The Utility of PET in Intensity Modulated Radiotherapy Planning**
(O-57) Dr Lee Sze Ting, Centre For PET, Austin Hospital & Ludwig Institute For Cancer Research, Heidelberg, Australia

0850 – 0910 **Prognostication in Radionuclide Therapy**
(O-58) Prof Sobhan Vinjamuri, Nuclear Medicine Dept, Royal Liverpool University Hospital, Liverpool, UK

0910 – 0930 **The 3-D Dosimetry in Radionuclide Therapy Based on 4D SPECT/CT Acquisition**
(O-59) Prof Kalevi Kairemo, Molecular Radiotherapy & Nuclear Medicine, International Comprehensive Cancer Center Docrates, Helsinki, Finland

0930 – 0950 **Dosimetry in Solid Tumours – Does it have Any Use**
(O-60) Prof John Buscombe, Nuclear Medicine, Royal Free Hospital, Cambridge, UK

0950 – 1010 **Current Knowledge of FET use in PET**
(O-61) Dr Malkowski Bogdan, Department of Nuclear Medicine, Oncology Centre, Bydgoszcz, Poland

1010 – 1030 **The Tracer Principle: From De Hevesy's Cup of Tea to the Secret Services?**
(O-62) Prof Alan Perkins, Radiological And Imaging Sciences, Nottingham University Hospitals, Nottingham, United Kingdom

1030 – 1100 **COFFEE / TEA / TRADE EXHIBITION** Ben Thanh Hall Foyer
Pre-Function Area, Level 1

POSTER PRESENTATIONS: MISCELLANEOUS

Ben Thanh Hall Foyer
Pre-Function Area, Level 1

Session Coordinators:

1. Ms Dang Truong Ka My, PET-CT and Cyclotron, Cho Ray Hospital, Ho Chi Minh, Vietnam
2. Dr Nguyen Thi Thuy Hang, Vietnam

(P-114) **Plasma Therapy: A New Era of Therapeutic Techniques**
Dr Tanvir Ahmed Biman, Scintigraphy Division, Nuclear Medicine, Institute of Nuclear Medicine & Ultrasound, Dhaka, Bangladesh

(P-115) **Early Outcome of Chemotherapy in Lymphoma Patients Using Tc-99m Tetrofosmin Scintigraphy**
Dr Muhammad Asif Rafique, Nuclear Medicine, Nuclear Medicine, Oncology And Radiotherapy Institute (NORI), Islamabad, Pakistan

(P-116) **Preparation of In-111 Oxine for Labeling of Stem Cell**
Prof Ali Sattari, Nuclear Medicine, Agriculture And Medicine Research School, Karadj, Iran

(P-117) **Sentinel Lymph Node Biopsy In Malignant Melanoma – Role of Lymphoscintigraphy in the Detection of Unpredictable Lymphatic Drainage**
Dr Zamfirescu Anca, Metabolic Radiotherapy, Bucharest Oncology Institute, Bucharest, Romania

(P-118) **Dual-Phase Tc99m-MIBI Scintigraphy in Lymphoma as a Predictor of Response to Chemotherapy**
Dr Zaheer Chirag, Nuclear Medicine, BINO Cancer Hospital, Bahawalpur Pakistan

(P-119) **Review of Utilization of Surveillance Scans in Lymphoma Patients – A Pilot Study**
Dr Judy Nguyen, Nuclear Medicine, Stanford University Medical Center, Stanford, USA

4th International Conference on Radiopharmaceutical Therapy (ICRT 2011)

In Conjunction with 10th AGM of Asian Regional Cooperative Council for Nuclear Medicine (ARCCNM)

28 Nov – 2 Dec 2011

New World Saigon Hotel, Ho Chi Minh City, Vietnam

DAY 4: THURSDAY, 1 DECEMBER 2011 (CONT'D)

1100 – 1245	SCIENTIFIC SESSION 10: BREAST CANCER, LYMPHOMA, RADIOIMMUNOTHERAPY (RIT)	Ben Thanh Hall, Level 1
	Session Chairpersons 1. Prof Hiroshi Toyama, Radiology, Fujita Health University, Toyoake, Japan 2. Dr Felix Sundram, Nuclear Medicine, Wijaya International and Sime Darby Medical Centres, Kuala Lumpur, Malaysia	
1100 – 1130 (O-63)	IART in Breast Cancer Prof Giovanni Paganelli, Divisione Di Medicina Nucleare, IEO Istituto Europeo Di Oncologia, Milano, Italy	
1130 – 1150 (O-64)	Positron Emission Tomography in Breast Cancer Dr Patricia Bernal Trujillo, Nuclear Medicine, Fundacion Santa Fe B Ogota, Colombia	
1130 – 1210 (O-65)	Radioimmuno-Scintigraphy and Radioimmuno-Therapy. A State of the Art Prof Izak Garty, Nuclear Medicine, Haemek Medical Centre, Afula, Israel	
1210 – 1230 (O-66)	Radioimmunotherapy of Non-Hodgkin Lymphoma with 131I-Rituximab Prof Harvey Turner, University Of Western Australia, Fremantle Hospital, Australia	
1230 – 1245 (O-67)	Use of PET to Monitor the Results of I-131 CHT25 RIT Dr Ewa Nowosinska, Nuclear Medicine Department, Royal Free Hospital, London, UK	
1245 – 1315	ORAL PRESENTATIONS	Ben Thanh Hall, Level 1
1245 – 1255 (O-68)	Potential Use of 177Lu In Radioimmunotherapy as Targeting Tracers on Monoclonal Antibodies Dr Choi Sun-Ju, Radioisotope Research Division, Korea Atomic Energy Research Institute, Daejeon, Korea	
1255 – 1305 (O-69)	Effect of Molecular Imaging on Evaluation of the Therapeutic Efficacy of VEGFR2 Blocking Antibody in a Sodium-Iodide Symporter Gene Expressed Tumor Model Dr Cheong Su-Jin, Nuclear Medicine, Chonbuk National University Medical School and Hospital, Jeonju, Korea	
1305 – 1315 (O-70)	Diagnostic Efficacy of Scintimammography for Detection of Malignant Tissue in the Breast Performed with Tc-99m MDP and Tc-99m Sestamibi Prof Birendra Kishore Das, Nuclear Medicine, Utkal Institute of Nuclear Medicine, Bhubaneswar, India	
1315 – 1400	LUNCH / TRADE EXHIBITION	
1400 – 1530	SCIENTIFIC SESSION 11: RADIONUCLIDE THERAPY & QUALITY OF LIFE	Ben Thanh Hall, Level 1
	Session Chairpersons: 1. Prof Irene Virgolini, Nuclear Medicine & PET, University Of Innsbruck, Innsbruck, Austria 2. Prof Abdelhamid Elgazzar, Nuclear Medicine & PET, Faculty of Medicine University of Kuwait, Kuwait	
1400 – 1425 (O-71)	The Value of Life and the Concept of QOL: A Critical Examination of the Basic Principles for Clinical Measurement of QOL Dr Remigius Orjiukwu, Nuclear Medicine, Medical University Innsbruck, Innsbruck, Austria	
1425 – 1450 (O-72)	QOL from A Doctor's Perspective : Review of Actual Clinical Data Prof Irene Virgolini, Nuclear Medicine & PET, University Of Innsbruck, Innsbruck, Austria	
1450 – 1515 (O-73)	QOL from A Patient Perspective Mr William Claxton, CNETS, Singapore	
1515 – 1525	COFFEE / TEA / TRADE EXHIBITION	Ben Thanh Hall Foyer Pre-Function Area, Level 1

4th International Conference on Radiopharmaceutical Therapy (ICRT 2011)

In Conjunction with 10th AGM of Asian Regional Cooperative Council for Nuclear Medicine (ARCCNM)

28 Nov – 2 Dec 2011

New World Saigon Hotel, Ho Chi Minh City, Vietnam

DAY 4: THURSDAY, 1 DECEMBER 2011 (CONT'D)

1525 – 1550	SCIENTIFIC SESSION 12: RADIONUCLIDE THERAPY – FUTURE PERSPECTIVES & CLOSING CEREMONY	Ben Thanh Hall, Level 1
	Session Chairpersons: 1. Prof Ajit Kumar Padhy, Nuclear Medicine, Singapore General Hospital, Singapore (President-WARMTH) 2. Prof Henry Bom Hee-Seung, Nuclear Medicine, CNU Medical School, Hwasun, South Korea	
1525 – 1550 (O-74)	THERANOSTICS: From Molecular Imaging Using PET/CT with Ga-68 Labeled Tracers to Personalized Therapy Prof Richard Baum, Department of Nuclear Medicine, Center For PET/CT, Bad Berka, Germany	
1550 – 1700	CLOSING CEREMONY	Ben Thanh Hall, Level 1
1550 – 1600	AWARDS: <ul style="list-style-type: none">▪ BEST ORAL PRESENTATION – 3 PRIZES▪ BEST POSTER – 3 PRIZES	
1600 – 1607	NEXT CONFERENCE <ul style="list-style-type: none">▪ 3rd International Symposium on Radiopharmaceutical Therapy (ISRT-2012), Levi, Finland Prof Kalevi Kaieremo (Finland)	
1607 – 1615	5th International Conference on Radiopharmaceutical Therapy (ICRT-2013) (Selection of Venue)	
1615 – 1620	Closing Remarks Prof Henry Bom (ARCCNM)	
1620 – 1625	Closing Remarks Dr Nguyễn Trường Sơn (Cho Ray Hospital)	
1625 – 1630	Vote of Thanks Dr Nguyễn Xuân Cảnh (Local Organizing Secretary)	
1630 – 1700	Highlights & Closing Remarks Prof Ajit Kumar Padhy, President, WARMTH	
1710	SHUTTLE TRANSFER TO OENOPHILOUS DINNER	
1730 – 2300	ENTERTAINMENT & OENOPHILOUS DINNER	
2300	END OF DAY 4	

4th International Conference on Radiopharmaceutical Therapy (ICRT 2011)

In Conjunction with 10th AGM of Asian Regional Cooperative Council for Nuclear Medicine (ARCCNM)

28 Nov – 2 Dec 2011

New World Saigon Hotel, Ho Chi Minh City, Vietnam

DAY 5: FRIDAY, 2 DECEMBER 2011

0730 **Departure to Cu Chi Tunnels for Sight-Seeing Tour**

0930 –1130 **Cu Chi Tunnel Tour**

1130 –1230 **Ho Chi Minh Memorial**

1230 –1500 **LUNCH**

1600 **Return to Hotel**

Last Evening in Ho Chi Minh City

All Participants Will Have A Free Evening. This Evening's Dinner Is Not Included In The Lump-Sum. Participants Are Free To Go Out For Sight Seeing In The City With Friends Or Do Shopping; And Later For A Change Should Try Out Some Of The Delicious Vietnamese Cuisine For Dinner.

DAY 6: SATURDAY, 3 DECEMBER 2011

Post-Congress Tour of Siem Reap, Cambodia
